Ger‐Jan Sanderink

866 total citations
12 papers, 712 citations indexed

About

Ger‐Jan Sanderink is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ger‐Jan Sanderink has authored 12 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ger‐Jan Sanderink's work include Cancer therapeutics and mechanisms (4 papers), Atrial Fibrillation Management and Outcomes (3 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). Ger‐Jan Sanderink is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Atrial Fibrillation Management and Outcomes (3 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). Ger‐Jan Sanderink collaborates with scholars based in France, United States and Netherlands. Ger‐Jan Sanderink's co-authors include Gerhard J. Nohynek, Marie-Christine Bissery, A. Le Liboux, Bruno Boutouyrie, Marie‐Laure Ozoux, Umesh Shukla, Guy Montay, Sylvie Assadourian, Éric Raymond and Valérie Boige and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ger‐Jan Sanderink

12 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ger‐Jan Sanderink France 10 348 189 150 136 94 12 712
Maura A. Kraynak United States 13 431 1.2× 308 1.6× 51 0.3× 24 0.2× 77 0.8× 19 807
Yuanjue Sun China 18 426 1.2× 315 1.7× 132 0.9× 43 0.3× 119 1.3× 41 937
K Nakanishi Japan 19 189 0.5× 350 1.9× 46 0.3× 95 0.7× 90 1.0× 61 988
Con Panousis Australia 16 185 0.5× 279 1.5× 101 0.7× 49 0.4× 56 0.6× 33 989
Myoung Joo Kang South Korea 18 401 1.2× 229 1.2× 44 0.3× 40 0.3× 354 3.8× 53 929
Jaime Feliú Batlle Spain 11 337 1.0× 90 0.5× 188 1.3× 16 0.1× 105 1.1× 30 586
Anne Dyhl-Polk Denmark 16 654 1.9× 178 0.9× 393 2.6× 17 0.1× 163 1.7× 20 1.1k
Ming‐Shen Dai Taiwan 17 278 0.8× 206 1.1× 23 0.2× 22 0.2× 57 0.6× 71 771
Jackie Baker United States 7 238 0.7× 117 0.6× 17 0.1× 25 0.2× 166 1.8× 12 583

Countries citing papers authored by Ger‐Jan Sanderink

Since Specialization
Citations

This map shows the geographic impact of Ger‐Jan Sanderink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ger‐Jan Sanderink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ger‐Jan Sanderink more than expected).

Fields of papers citing papers by Ger‐Jan Sanderink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ger‐Jan Sanderink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ger‐Jan Sanderink. The network helps show where Ger‐Jan Sanderink may publish in the future.

Co-authorship network of co-authors of Ger‐Jan Sanderink

This figure shows the co-authorship network connecting the top 25 collaborators of Ger‐Jan Sanderink. A scholar is included among the top collaborators of Ger‐Jan Sanderink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ger‐Jan Sanderink. Ger‐Jan Sanderink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Mordt, Olaf Valverde, et al.. (2016). A DBS Method for Quantitation of The New Oral Trypanocidal Drug Fexinidazole and its Active Metabolites. Bioanalysis. 8(19). 2045–2063. 4 indexed citations
2.
Lunven, Catherine, et al.. (2016). Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide. Therapeutic Drug Monitoring. 38(4). 471–482. 14 indexed citations
3.
Sémiond, Dorothée, et al.. (2014). A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anti-Cancer Drugs. 26(3). 350–358. 13 indexed citations
4.
Cortez, Pierre, et al.. (2012). Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. British Journal of Clinical Pharmacology. 75(5). 1255–1264. 4 indexed citations
5.
Soepenberg, Otto, Herlinde Dumez, Jaap Verweij, et al.. (2005). Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors. Journal of Clinical Oncology. 23(4). 889–898. 25 indexed citations
6.
Soepenberg, Otto, Herlinde Dumez, Jaap Verweij, et al.. (2005). Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors. Clinical Cancer Research. 11(4). 1504–1511. 70 indexed citations
7.
Kuppens, I. E. L. M., W.W. ten Bokkel Huinink, Jos H. Beijnen, et al.. (2004). Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 55(3). 263–270. 25 indexed citations
8.
Bruno, René, Sylvie Retout, Nicole Vivier, et al.. (2003). Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction. British Journal of Clinical Pharmacology. 56(4). 407–414. 34 indexed citations
9.
Raymond, Éric, Valérie Boige, Sandrine Faivre, et al.. (2002). Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction. Journal of Clinical Oncology. 20(21). 4303–4312. 86 indexed citations
10.
Sanderink, Ger‐Jan, A. Le Liboux, Marie‐Laure Ozoux, et al.. (2002). The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology & Therapeutics. 72(3). 308–318. 144 indexed citations
11.
Bissery, Marie-Christine, et al.. (1995). Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I. Anti-Cancer Drugs. 6(3). 339–355. 284 indexed citations
12.
Sanderink, Ger‐Jan, Yves Artur, François Paillé, & Gérard Siest. (1989). Clinical significance of a new isoform of serum alanine aminopeptidase; relationship with liver disease and alcohol consumption. Clinica Chimica Acta. 179(1). 23–31. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maura A. Kraynak Breakdown of academic impact, for papers by Yuanjue Sun Breakdown of academic impact, for papers by K Nakanishi Breakdown of academic impact, for papers by Con Panousis Breakdown of academic impact, for papers by Myoung Joo Kang Breakdown of academic impact, for papers by Jaime Feliú Batlle Breakdown of academic impact, for papers by Anne Dyhl-Polk Breakdown of academic impact, for papers by Ming‐Shen Dai Breakdown of academic impact, for papers by Jackie Baker
Rankless by CCL
2026